Acute Myeloid Leukemia Clinical Trial

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Summary

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Prior morphologically confirmed diagnosis of AML based on WHO Criteria
Has previously failed all available and suitable therapies for AML Disease relapse or the presence of refractory disease after ≥ 2 cycles of chemotherapy must be documented by bone marrow (BM) examination demonstrating > 5% blasts in the BM not attributable to another cause. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC count is permitted.
Age ≥ 2 and ≤ 25 years
Body surface area (BSA) ≤ 2.10 m2, calculated per the Mostellar formula
Must be able to tolerate po or ng medications.
Performance status:

Subject age

≤ 16 years old: Lansky score ≥ 50 > 16 years old: Karnofsky score ≥ 50%

Life expectancy of greater than 4 weeks
Platelets ≥ 10,000/mm3 (for subjects with platelets < 10,000/mm3 at baseline, platelet transfusion support is allowed)
Serum creatinine ≤ 2.0 mg/dL or estimated creatinine clearance ≥ 30 mL/min (Cockcroft Gault) within 14 days prior to treatment initiation
Total bilirubin ≤ 2.0 x Institutional upper limit of normal (ULN) within 14 days prior to treatment initiation, unless the elevation is due primarily to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome or hemolysis or non hepatic origin, and not to liver dysfunction
SGOT (AST) ≤ 3.0 x ULN and SGPT (ALT) ≤ 3.0 x ULN within 14 days prior to treatment initiation
Females of reproductive potential (WOCBP) must have a negative pregnancy test within 14 days prior to study treatment.
WOCBP must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) for the duration of study participation
Men only: Men must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) prior to the study treatment (from date of consent), for the duration of study participation, and 30 days after completion of niclosamide administration
Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document containing an authorization to use protected health information (in accordance with national and local subject privacy regulations

Exclusion Criteria:

Received anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or investigational therapy) within 2 weeks prior to starting study treatment. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC is permitted.
Receiving any other investigational agents.
Unresolved toxicities due to prior anticancer therapy, defined as not having resolved to Grade 0 or 1 (by CTCAE version 5 criteria), unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia
Acute promyelocytic leukemia (French American British Class M3 AML)
Known active central nervous system (CNS) leukemia; subjects can enroll on study if CNS disease can be cleared with intrathecal chemotherapy, in the judgement of the treating physician
Prior bone marrow transplant presenting with active uncontrolled graft versus host disease (GvHD)
Known congenital bleeding disorders, including but not limited to hemophilia
Known active uncontrolled systemic infection
Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, uncontrolled symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction, at the time of study entry
Inability to receive administration of niclosamide in the available formulation(s)
Uncontrolled intercurrent illness including, but not limited to, uncontrolled active infection, or psychiatric illness/social situations that would limit compliance with study requirements
Lactating or pregnant female
Known active hepatitis C

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

16

Study ID:

NCT05188170

Recruitment Status:

Recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University
Palo Alto California, 94305, United States More Info
Nancy Sweeters, RN, PNP
Contact
650-721-4074
[email protected]
Kathleen Sakamoto, M.D., Ph.D
Principal Investigator
Adam Frymoyer, MD
Sub-Investigator
Meena Kadapakkam, MD
Sub-Investigator
Norman Lacayo, MD
Sub-Investigator
Namrata Patel, PharmD
Sub-Investigator
Rebecca Richards, M.D., Ph.D
Sub-Investigator
Jennifer Kamens, M.D
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

16

Study ID:

NCT05188170

Recruitment Status:

Recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.